Skip to main content
NCBI home page
The Journal of Cell Biology logoLink to The Journal of Cell Biology
. 1994 Dec 2;127(6):1923–1932. doi: 10.1083/jcb.127.6.1923

Transient immunosuppressive treatment leads to long-term retention of allogeneic myoblasts in hybrid myofibers

PMCID: PMC2120274  PMID: 7806570

Abstract

Normal and genetically engineered skeletal muscle cells (myoblasts) show promise as drug delivery vehicles and as therapeutic agents for treating muscle degeneration in muscular dystrophies. A limitation is the immune response of the host to the transplanted cells. Allogeneic myoblasts are rapidly rejected unless immunosuppressants are administered. However, continuous immunosuppression is associated with significant toxic side effects. Here we test whether immunosuppressive treatment, administered only transiently after allogeneic myoblast transplantation, allows the long-term survival of the transplanted cells in mice. Two immunosuppressive treatments with different modes of action were used: (a) cyclosporine A (CSA); and (b) monoclonal antibodies to intracellular adhesion molecule-1 and leukocyte function- associated molecule-1. The use of myoblasts genetically engineered to express beta-galactosidase allowed quantitation of the survival of allogeneic myoblasts at different times after cessation of the immunosuppressive treatments. Without host immunosuppression, allogeneic myoblasts were rejected from all host strains tested, although the relative time course differed as expected for low and high responder strains. The allogeneic myoblasts initially fused with host myofibers, but these hybrid cells were later destroyed by the massive immunological response of the host. However, transient immunosuppressive treatment prevented the hybrid myofiber destruction and led to their long-term retention. Even four months after the cessation of treatment, the hybrid myofibers persisted and no inflammatory infiltrate was present in the tissue. Such long-term survival indicates that transient immunosuppression may greatly increase the utility of myoblast transplantation as a therapeutic approach to the treatment of muscle and nonmuscle disease.

Full Text

The Full Text of this article is available as a PDF (5.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appleyard S. T., Dunn M. J., Dubowitz V., Rose M. L. Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders. Lancet. 1985 Feb 16;1(8425):361–363. doi: 10.1016/s0140-6736(85)91384-4. [DOI] [PubMed] [Google Scholar]
  2. Arbonés M. L., Austin H. A., Capon D. J., Greenburg G. Gene targeting in normal somatic cells: inactivation of the interferon-gamma receptor in myoblasts. Nat Genet. 1994 Jan;6(1):90–97. doi: 10.1038/ng0194-90. [DOI] [PubMed] [Google Scholar]
  3. Auchincloss H., Jr, Winn H. J. Murine CD8+ T cell helper function is particularly sensitive to cyclosporine suppression in vivo. J Immunol. 1989 Dec 15;143(12):3940–3943. [PubMed] [Google Scholar]
  4. Barr E., Leiden J. M. Systemic delivery of recombinant proteins by genetically modified myoblasts. Science. 1991 Dec 6;254(5037):1507–1509. doi: 10.1126/science.1962212. [DOI] [PubMed] [Google Scholar]
  5. Benjamin R. J., Qin S. X., Wise M. P., Cobbold S. P., Waldmann H. Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination. Eur J Immunol. 1988 Jul;18(7):1079–1088. doi: 10.1002/eji.1830180717. [DOI] [PubMed] [Google Scholar]
  6. Blau H. M., Chiu C. P., Webster C. Cytoplasmic activation of human nuclear genes in stable heterocaryons. Cell. 1983 Apr;32(4):1171–1180. doi: 10.1016/0092-8674(83)90300-8. [DOI] [PubMed] [Google Scholar]
  7. Blau H. M., Dhawan J., Pavlath G. K. Myoblasts in pattern formation and gene therapy. Trends Genet. 1993 Aug;9(8):269–274. doi: 10.1016/0168-9525(93)90012-7. [DOI] [PubMed] [Google Scholar]
  8. Blau H. M., Pavlath G. K., Hardeman E. C., Chiu C. P., Silberstein L., Webster S. G., Miller S. C., Webster C. Plasticity of the differentiated state. Science. 1985 Nov 15;230(4727):758–766. doi: 10.1126/science.2414846. [DOI] [PubMed] [Google Scholar]
  9. Blau H. M., Webster C., Pavlath G. K. Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 1983 Aug;80(15):4856–4860. doi: 10.1073/pnas.80.15.4856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Borel J. F. Pharmacology of cyclosporine (sandimmune). IV. Pharmacological properties in vivo. Pharmacol Rev. 1990 Sep;41(3):259–371. [PubMed] [Google Scholar]
  11. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  12. Brooke M. H., Fenichel G. M., Griggs R. C., Mendell J. R., Moxley R. T., 3rd, Miller J. P., Kaiser K. K., Florence J. M., Pandya S., Signore L. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol. 1987 Aug;44(8):812–817. doi: 10.1001/archneur.1987.00520200016010. [DOI] [PubMed] [Google Scholar]
  13. Butcher G. W., Howard J. C. Genetic control of transplant rejection. Transplantation. 1982 Oct;34(4):161–166. [PubMed] [Google Scholar]
  14. Calne R. Y., Rolles K., White D. J., Thiru S., Evans D. B., McMaster P., Dunn D. C., Craddock G. N., Henderson R. G., Aziz S. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979 Nov 17;2(8151):1033–1036. doi: 10.1016/s0140-6736(79)92440-1. [DOI] [PubMed] [Google Scholar]
  15. Charlton B., Guymer R. H., Slattery R. M., Mandel T. E. Intercellular adhesion molecule (ICAM-1) inhibition can induce tolerance in vivo. Immunol Cell Biol. 1991 Apr;69(Pt 2):89–93. doi: 10.1038/icb.1991.14. [DOI] [PubMed] [Google Scholar]
  16. Cifuentes-Diaz C., Delaporte C., Dautréaux B., Charron D., Fardeau M. Class II MHC antigens in normal human skeletal muscle. Muscle Nerve. 1992 Mar;15(3):295–302. doi: 10.1002/mus.880150307. [DOI] [PubMed] [Google Scholar]
  17. Cosimi A. B., Conti D., Delmonico F. L., Preffer F. I., Wee S. L., Rothlein R., Faanes R., Colvin R. B. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol. 1990 Jun 15;144(12):4604–4612. [PubMed] [Google Scholar]
  18. Dai Y., Roman M., Naviaux R. K., Verma I. M. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10892–10895. doi: 10.1073/pnas.89.22.10892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. DeSilva S., Drachman D. B., Mellits D., Kuncl R. W. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol. 1987 Aug;44(8):818–822. doi: 10.1001/archneur.1987.00520200022012. [DOI] [PubMed] [Google Scholar]
  20. Dhawan J., Pan L. C., Pavlath G. K., Travis M. A., Lanctot A. M., Blau H. M. Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science. 1991 Dec 6;254(5037):1509–1512. doi: 10.1126/science.1962213. [DOI] [PubMed] [Google Scholar]
  21. Emslie-Smith A. M., Arahata K., Engel A. G. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989 Mar;20(3):224–231. doi: 10.1016/0046-8177(89)90128-7. [DOI] [PubMed] [Google Scholar]
  22. Faustman D., Coe C. Prevention of xenograft rejection by masking donor HLA class I antigens. Science. 1991 Jun 21;252(5013):1700–1702. doi: 10.1126/science.1710828. [DOI] [PubMed] [Google Scholar]
  23. Fenichel G. M., Florence J. M., Pestronk A., Mendell J. R., Moxley R. T., 3rd, Griggs R. C., Brooke M. H., Miller J. P., Robison J., King W. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 1991 Dec;41(12):1874–1877. doi: 10.1212/wnl.41.12.1874. [DOI] [PubMed] [Google Scholar]
  24. Fischer A., Griscelli C., Blanche S., Le Deist F., Veber F., Lopez M., Delaage M., Olive D., Mawas C., Janossy G. Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone-marrow transplantation. Lancet. 1986 Nov 8;2(8515):1058–1061. doi: 10.1016/s0140-6736(86)90465-4. [DOI] [PubMed] [Google Scholar]
  25. Green C. J., Allison A. C. Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment. Lancet. 1978 Jun 3;1(8075):1182–1183. doi: 10.1016/s0140-6736(78)90970-4. [DOI] [PubMed] [Google Scholar]
  26. Green C. J., Allison A. C., Precious S. Induction of specific tolerance in rabbits by kidney allografting and short periods of cyclosporin-A treatment. Lancet. 1979 Jul 21;2(8134):123–125. doi: 10.1016/s0140-6736(79)90005-9. [DOI] [PubMed] [Google Scholar]
  27. Griggs R. C., Moxley R. T., 3rd, Mendell J. R., Fenichel G. M., Brooke M. H., Pestronk A., Miller J. P., Cwik V. A., Pandya S., Robison J. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) Neurology. 1993 Mar;43(3 Pt 1):520–527. doi: 10.1212/wnl.43.3_part_1.520. [DOI] [PubMed] [Google Scholar]
  28. Gussoni E., Pavlath G. K., Lanctot A. M., Sharma K. R., Miller R. G., Steinman L., Blau H. M. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature. 1992 Apr 2;356(6368):435–438. doi: 10.1038/356435a0. [DOI] [PubMed] [Google Scholar]
  29. Hardiman O., Faustman D., Li X., Sklar R. M., Brown R. H., Jr Expression of major histocompatibility complex antigens in cultures of clonally derived human myoblasts. Neurology. 1993 Mar;43(3 Pt 1):604–608. doi: 10.1212/wnl.43.3_part_1.604. [DOI] [PubMed] [Google Scholar]
  30. Hardiman O., Sklar R. M., Brown R. H., Jr Direct effects of cyclosporin A and cyclophosphamide on differentiation of normal human myoblasts in culture. Neurology. 1993 Jul;43(7):1432–1434. doi: 10.1212/wnl.43.7.1432. [DOI] [PubMed] [Google Scholar]
  31. Haug C. E., Colvin R. B., Delmonico F. L., Auchincloss H., Jr, Tolkoff-Rubin N., Preffer F. I., Rothlein R., Norris S., Scharschmidt L., Cosimi A. B. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation. 1993 Apr;55(4):766–773. doi: 10.1097/00007890-199304000-00016. [DOI] [PubMed] [Google Scholar]
  32. Heagy W., Waltenbaugh C., Martz E. Potent ability of anti-LFA-1 monoclonal antibody to prolong allograft survival. Transplantation. 1984 May;37(5):520–523. doi: 10.1097/00007890-198405000-00021. [DOI] [PubMed] [Google Scholar]
  33. Honda H., Rostami A. Expression of major histocompatibility complex class I antigens in rat muscle cultures: the possible developmental role in myogenesis. Proc Natl Acad Sci U S A. 1989 Sep;86(18):7007–7011. doi: 10.1073/pnas.86.18.7007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Huard J., Roy R., Guérette B., Verreault S., Tremblay G., Tremblay J. P. Human myoblast transplantation in immunodeficient and immunosuppressed mice: evidence of rejection. Muscle Nerve. 1994 Feb;17(2):224–234. doi: 10.1002/mus.880170214. [DOI] [PubMed] [Google Scholar]
  35. Hughes S. M., Blau H. M. Muscle fiber pattern is independent of cell lineage in postnatal rodent development. Cell. 1992 Feb 21;68(4):659–671. doi: 10.1016/0092-8674(92)90142-y. [DOI] [PubMed] [Google Scholar]
  36. Ilano A. L., McConnell M. V., Gurley K. E., Spinelli A., Pearce N. W., Hall B. M. Cellular basis of allograft rejection in vivo. V. Examination of the mechanisms responsible for the differing efficacy of monoclonal antibody to CD4+ T cell subsets in low- and high-responder rat strains. J Immunol. 1989 Nov 1;143(9):2828–2836. [PubMed] [Google Scholar]
  37. Isobe M., Yagita H., Okumura K., Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 1992 Feb 28;255(5048):1125–1127. doi: 10.1126/science.1347662. [DOI] [PubMed] [Google Scholar]
  38. Jiao S., Gurevich V., Wolff J. A. Long-term correction of rat model of Parkinson's disease by gene therapy. Nature. 1993 Apr 1;362(6419):450–453. doi: 10.1038/362450a0. [DOI] [PubMed] [Google Scholar]
  39. Karpati G., Ajdukovic D., Arnold D., Gledhill R. B., Guttmann R., Holland P., Koch P. A., Shoubridge E., Spence D., Vanasse M. Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol. 1993 Jul;34(1):8–17. doi: 10.1002/ana.410340105. [DOI] [PubMed] [Google Scholar]
  40. Karpati G., Carpenter S., Prescott S. Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve. 1988 Aug;11(8):795–803. doi: 10.1002/mus.880110802. [DOI] [PubMed] [Google Scholar]
  41. Karpati G., Pouliot Y., Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol. 1988 Jan;23(1):64–72. doi: 10.1002/ana.410230111. [DOI] [PubMed] [Google Scholar]
  42. Labrecque C., Roy R., Tremblay J. P. Immune reactions after myoblast transplantation in mouse muscles. Transplant Proc. 1992 Dec;24(6):2889–2892. [PubMed] [Google Scholar]
  43. Law P. K., Goodwin T. G., Fang Q., Duggirala V., Larkin C., Florendo J. A., Kirby D. S., Deering M. B., Li H. J., Chen M. Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys. Cell Transplant. 1992;1(2-3):235–244. doi: 10.1177/0963689792001002-305. [DOI] [PubMed] [Google Scholar]
  44. Martz E. LFA-1 and other accessory molecules functioning in adhesions of T and B lymphocytes. Hum Immunol. 1987 Jan;18(1):3–37. doi: 10.1016/0198-8859(87)90110-8. [DOI] [PubMed] [Google Scholar]
  45. McDouall R. M., Dunn M. J., Dubowitz V. Expression of class I and class II MHC antigens in neuromuscular diseases. J Neurol Sci. 1989 Feb;89(2-3):213–226. doi: 10.1016/0022-510x(89)90023-3. [DOI] [PubMed] [Google Scholar]
  46. Mendell J. R., Moxley R. T., Griggs R. C., Brooke M. H., Fenichel G. M., Miller J. P., King W., Signore L., Pandya S., Florence J. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989 Jun 15;320(24):1592–1597. doi: 10.1056/NEJM198906153202405. [DOI] [PubMed] [Google Scholar]
  47. Nagao T., White D. J., Calne R. Y. Kinetics of unresponsiveness induced by a short course of cyclosporin A. Transplantation. 1982 Jan;33(1):31–35. doi: 10.1097/00007890-198201000-00007. [DOI] [PubMed] [Google Scholar]
  48. Ortega J. D., Sagen J., Pappas G. D. Short-term immunosuppression enhances long-term survival of bovine chromaffin cell xenografts in rat CNS. Cell Transplant. 1992;1(1):33–41. doi: 10.1177/096368979200100107. [DOI] [PubMed] [Google Scholar]
  49. Partridge T. Skeletal muscle as a target for gene therapy. Gene Ther. 1994 Mar;1(2):77–79. [PubMed] [Google Scholar]
  50. Ponder B. A., Wilkinson M. M., Wood M., Westwood J. H. Immunohistochemical demonstration of H2 antigens in mouse tissue sections. J Histochem Cytochem. 1983 Jul;31(7):911–919. doi: 10.1177/31.7.6343482. [DOI] [PubMed] [Google Scholar]
  51. Price J., Thurlow L. Cell lineage in the rat cerebral cortex: a study using retroviral-mediated gene transfer. Development. 1988 Nov;104(3):473–482. doi: 10.1242/dev.104.3.473. [DOI] [PubMed] [Google Scholar]
  52. Prieto J., Takei F., Gendelman R., Christenson B., Biberfeld P., Patarroyo M. MALA-2, mouse homologue of human adhesion molecule ICAM-1 (CD54). Eur J Immunol. 1989 Sep;19(9):1551–1557. doi: 10.1002/eji.1830190906. [DOI] [PubMed] [Google Scholar]
  53. Rando T. A., Blau H. M. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol. 1994 Jun;125(6):1275–1287. doi: 10.1083/jcb.125.6.1275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Rosenberg A. S., Mizuochi T., Sharrow S. O., Singer A. Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection. J Exp Med. 1987 May 1;165(5):1296–1315. doi: 10.1084/jem.165.5.1296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Rowe D., Isenberg D. A., Beverley P. C. Monoclonal antibodies to human leucocyte antigens in polymyositis and muscular dystrophy. Clin Exp Immunol. 1983 Nov;54(2):327–336. [PMC free article] [PubMed] [Google Scholar]
  56. Salminen A., Elson H. F., Mickley L. A., Fojo A. T., Gottesman M. M. Implantation of recombinant rat myocytes into adult skeletal muscle: a potential gene therapy. Hum Gene Ther. 1991 Spring;2(1):15–26. doi: 10.1089/hum.1991.2.1-15. [DOI] [PubMed] [Google Scholar]
  57. Sanes J. R., Rubenstein J. L., Nicolas J. F. Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J. 1986 Dec 1;5(12):3133–3142. doi: 10.1002/j.1460-2075.1986.tb04620.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Sarmiento M., Dialynas D. P., Lancki D. W., Wall K. A., Lorber M. I., Loken M. R., Fitch F. W. Cloned T lymphocytes and monoclonal antibodies as probes for cell surface molecules active in T cell-mediated cytolysis. Immunol Rev. 1982;68:135–169. doi: 10.1111/j.1600-065x.1982.tb01063.x. [DOI] [PubMed] [Google Scholar]
  59. Schubert W. Triple immunofluorescence confocal laser scanning microscopy: spatial correlation of novel cellular differentiation markers in human muscle biopsies. Eur J Cell Biol. 1991 Aug;55(2):272–285. [PubMed] [Google Scholar]
  60. Sharma K. R., Mynhier M. A., Miller R. G. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology. 1993 Mar;43(3 Pt 1):527–532. doi: 10.1212/wnl.43.3_part_1.527. [DOI] [PubMed] [Google Scholar]
  61. Sprent J., Schaefer M., Lo D., Korngold R. Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J Exp Med. 1986 Apr 1;163(4):998–1011. doi: 10.1084/jem.163.4.998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Springer T. A. Adhesion receptors of the immune system. Nature. 1990 Aug 2;346(6283):425–434. doi: 10.1038/346425a0. [DOI] [PubMed] [Google Scholar]
  63. Springer T. A., Dustin M. L., Kishimoto T. K., Marlin S. D. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol. 1987;5:223–252. doi: 10.1146/annurev.iy.05.040187.001255. [DOI] [PubMed] [Google Scholar]
  64. Stewart R., Stephenson P., Godden U., Butcher G., Roser B. Graft rejection in a congenic panel of rats with defined immune response genes for class I antigens. II. Quantitative aspects of Ir gene function in a full-haplotype mismatch. Transplantation. 1985 Oct;40(4):432–436. doi: 10.1097/00007890-198510000-00017. [DOI] [PubMed] [Google Scholar]
  65. Tremblay J. P., Bouchard J. P., Malouin F., Théau D., Cottrell F., Collin H., Rouche A., Gilgenkrantz S., Abbadi N., Tremblay M. Myoblast transplantation between monozygotic twin girl carriers of Duchenne muscular dystrophy. Neuromuscul Disord. 1993 Sep-Nov;3(5-6):583–592. doi: 10.1016/0960-8966(93)90121-y. [DOI] [PubMed] [Google Scholar]
  66. Tremblay J. P., Malouin F., Roy R., Huard J., Bouchard J. P., Satoh A., Richards C. L. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant. 1993 Mar-Apr;2(2):99–112. doi: 10.1177/096368979300200203. [DOI] [PubMed] [Google Scholar]
  67. Waldmann H., Cobbold S. Monoclonal antibodies for the induction of transplantation tolerance. Curr Opin Immunol. 1993 Oct;5(5):753–758. doi: 10.1016/0952-7915(93)90133-d. [DOI] [PubMed] [Google Scholar]
  68. Waldmann H. Manipulation of T-cell responses with monoclonal antibodies. Annu Rev Immunol. 1989;7:407–444. doi: 10.1146/annurev.iy.07.040189.002203. [DOI] [PubMed] [Google Scholar]
  69. Watt D. J. A comparison of long-term survival of muscle precursor cell suspensions and minced muscle allografts in the non-tolerant mouse. Adv Exp Med Biol. 1990;280:35–39. doi: 10.1007/978-1-4684-5865-7_6. [DOI] [PubMed] [Google Scholar]
  70. Watt D. J., Morgan J. E., Partridge T. A. Long term survival of allografted muscle precursor cells following a limited period of treatment with cyclosporin A. Clin Exp Immunol. 1984 Feb;55(2):419–426. [PMC free article] [PubMed] [Google Scholar]
  71. Watt D. J., Partridge T. A., Sloper J. C. Cyclosporin A as a means of preventing rejection of skeletal muscle allografts in mice. Transplantation. 1981 Apr;31(4):266–271. doi: 10.1097/00007890-198104000-00007. [DOI] [PubMed] [Google Scholar]
  72. Webster C., Blau H. M. Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somat Cell Mol Genet. 1990 Nov;16(6):557–565. doi: 10.1007/BF01233096. [DOI] [PubMed] [Google Scholar]
  73. Webster C., Pavlath G. K., Parks D. R., Walsh F. S., Blau H. M. Isolation of human myoblasts with the fluorescence-activated cell sorter. Exp Cell Res. 1988 Jan;174(1):252–265. doi: 10.1016/0014-4827(88)90159-0. [DOI] [PubMed] [Google Scholar]
  74. White D. J., Lim S. M. The induction of tolerance by cyclosporine. Transplantation. 1988 Aug;46(2 Suppl):118S–121S. doi: 10.1097/00007890-198808001-00022. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Cell Biology are provided here courtesy of The Rockefeller University Press

RESOURCES